Novartis will be waiting for the results of the COVID-ARDS trial in the US. Once it gets that, then I expect at least a further 14-21 days to analyse and discuss the results. Furthermore they would need to analyse if its worth to renegotiate the deal struck with MSB Board, or they walk away and restart anew with them. A lot of the signing on would have been hinging on the COVID ARDS trial back in Nov 2020 when FDA and DSMB were still favourable for Rem-L treating Covid ARDS...since that news has come and passed, things have changed...
Deadline for Novartis, page-6
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
0.030(1.90%) |
Mkt cap ! $1.832B | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.65 | $1.59 | $7.014M | 4.343M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 342 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.61 | 54534 | 8 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |